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Abstract
Phosphorylation patterns of the C-terminal domain (CTD) of largest
subunit of RNA polymerase II (called the CTD code) orchestrate the
recruitment of RNA processing and transcription factors. Recent
studies showed that not only serines and tyrosines but also thre-
onines of the CTD can be phosphorylated with a number of
functional consequences, including the interaction with yeast tran-
scription termination factor, Rtt103p. Here, we report the solution
structure of the Rtt103p CTD-interacting domain (CID) bound to
Thr4 phosphorylated CTD, a poorly understood letter of the CTD
code. The structure reveals a direct recognition of the phospho-
Thr4 mark by Rtt103p CID and extensive interactions involving resi-
dues from three repeats of the CTD heptad. Intriguingly, Rtt103p’s
CID binds equally well Thr4 and Ser2 phosphorylated CTD. A doubly
phosphorylated CTD at Ser2 and Thr4 diminishes its binding affinity
due to electrostatic repulsion. Our structural data suggest that the
recruitment of a CID-containing CTD-binding factor may be coded
by more than one letter of the CTD code.
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Introduction
RNA polymerase II (RNAPII) utilizes a long and flexible carboxyl-
terminal domain (CTD) of its largest subunit to specifically recruit
protein/RNA-binding factors during transcription [1–5]. The CTD
consists of tandem repeats with conserved consensus Tyr1-Ser2-
Pro3-Thr4-Ser5-Pro6-Ser7 that is repeated 26 times in yeast and 52
times in humans [6]. The CTD sequence is post-translationally phos-
phorylated at serines (Ser2, Ser5 and Ser7) and Tyr1 in a dynamic
manner, yielding specific patterns that are recognized by appropriate
factors in coordination with the transcription cycle events [3–5,7].
Additionally another highly conserved position, Thr4, was
reported to be phosphorylated both in yeast and humans [8–12].
However, the levels of pThr4 in cells remain controversial based on
two recent mass-spectrometry studies [10,11]. Substitution of Thr4 to
Ala (T4A) or Val (T4V) is lethal for chicken and human cells [12–14];
however, the same mutants are viable in yeast [9,15,16]. In humans,
genomewide studies revealed increasing levels of pThr4 throughout
the gene body with the peak after the poly-A site [12]. In agreement
with this, the T4A mutant showed defect in transcription elongation
[12]. In yeast, the pThr4-mark is enriched along the whole gene body,
similarly to the pTyr1-mark [17]. Both marks go down prior recruit-
ment of transcription termination factors [17]. Therefore, it was
suggested that the pThr4 mark along with the pTyr1-mark prevent
binding of transcription termination factors during transcription
elongation [17]. However, recent high resolution ChiP-nexus data
suggested a different role for the pThr4 mark involved in transcrip-
tion termination and post-transcriptional splicing [18].
It has been unclear for a long time what protein factors are
recruited through the pThr4 signal. Interestingly, yeast transcription
termination factor, Rtt103p, well known to be associated with the
pSer2-mark [17,19,20], was identified as a part of the interactome of
RNAPII phosphorylated at Thr4 [18]. Based on the overlay of NET-
seq and ChIP-nexus profiles, Rtt103p coincides with the pThr4 mark
after poly-A site. Both, deletion of the entire Rtt103p protein or
expression of Rpb1 T4V CTD mutant, cause similar RNAPII pausing
defect after poly-A site. The authors suggested a model, in which
both pSer2 and pThr4 marks can contribute to the recruitment of
Rtt103p to the poly-A site [18]. This concept is also supported by
recent mass-spectrometry analyses of RNAPII CTD population
pulled down by Rtt103p, which revealed simultaneous presence of
pThr4 and pSer2 marks [11].
To understand the puzzling roles of the pSer2 and pThr4 marks in
recruitment of transcription termination factor Rtt103p, we solved
NMR structure of the pThr4 CTD peptide in complex with Rtt103p
CTD-interacting domain (CID). Our structure reveals for the first
time a direct readout of the pThr4 mark within the CTD. We also
reveal significantly larger interaction area of Rtt103p with the CTD
peptide than previously reported [20]. Next, we show that two adja-
cently positioned phosphorylations, pSer2 followed by pThr4, inhibit
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the binding of Rtt103p CID due to a charge–charge repulsion of the
two closely positioned phosphate moieties. Finally, we propose that
the CTD code is degenerated, as Rtt103p reads the pThr4 and pSer2
marks equally well using the same molecular mechanism.
Results and Discussion
Rtt103p CID binds equally well Thr4 and Ser2 phosphomarks
To test the binding affinity of Rtt103p CID towards pThr4-CTD
in vitro, we performed an equilibrium-binding assay using
fluorescence anisotropy (FA) (Fig 1B). The experiment revealed that
Rtt103p binds pThr4-CTD with a KD of 15  1 lM, which is 2.5
times weaker binding than to the CTD with the pSer2 mark
(KD = 6.0  0.2 lM). This finding is in a good agreement with
previous co-immunoprecipitation studies, where Rtt103p was pulled
down by RNAPII with the pThr4 mark and successfully competed
out by pSer2-CTD or pThr4-CTD antisera [18]. Doubly phosphory-
lated pThr4-CTD at both Thr4 displayed increased binding affinity
due to avidity effects (KD = 6  0.2 lM). Remarkably, if the pSer2
and pThr4 marks are positioned adjacently, binding affinity
(KD = 43  2 lM) is lowered almost to the level of non-phosphory-
lated CTD (KD = 64  2 lM). The pSer5 phosphorylation mark was
A
B
Figure 1. How CTD phosphorylations modulate binding to Rtt103p CID.
A Numbering of residues and order of heptad repeats of the CTD peptide used throughout the study.
B Equilibrium binding of Rtt103p CID with fluorescently labelled CTD peptides monitored by fluorescence anisotropy (FA). Rtt103p CID titrated into 10 nM FAM-labelled
CTD peptides. Peptide sequences, corresponding binding isotherms and dissociation constant (KD,  standard deviation of the fit) are shown. FAM, 5,6-
carboxyfluorescein. N.D., not determined.
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also previously shown to abolish and lower the binding with
Rtt103p or its close human homologue [20,21]. Next, we introduced
the pTyr1 mark to the central heptad of the CTD peptide, which
completely abolished the binding with Rtt103p (Fig 1B). This
suggests that Y1b is accommodated in the hydrophobic pocket
following the previously established binding model for CIDs [17].
NMR structure of Rtt103p CID bound to CTD with
phospho-threonine mark
To reveal the structural basis of pThr4 recognition, we solved solu-
tion structure of a reconstituted complex that harbours Rtt103p CID


















































































































Q19A, KD= 48 ± 5
K72E, KD= 54 ± 3
R108N, KD= 38 ± 2








Figure 2. Solution structure of Rtt103p CID in complex with pThr4-CTD.
A Overlay of the 20 lowest energy structures of Rtt103p CID (black ribbon) complexed with pThr4-CTD (red ribbon) shown in stereo. N- and C-termini of the protein
and peptide are indicated.
B Solution structure of Rtt103p CID (grey helices) bound to the pThr4-CTD peptide (magenta sticks). Highlighted Rtt103p CID residues (grey sticks, blue labels) form
hydrophobic contacts and putative hydrogen bonds (dashed black lines) with pThr4-CTD peptide.
C Schematic diagram of Rtt103p CID (blue) and pThr4-CTD (black) interactions (hydrophobic contacts, spoked arcs; hydrogen bonds, dashed lines).
D Equilibrium binding of Rtt103p CID mutants with pThr4-CTD peptide monitored by fluorescence anisotropy (FA). Rtt103p CID mutants titrated into 10 nM FAM-
labelled CTD peptides. Corresponding binding isotherms and KDs ( standard deviation of the fit) are shown. FAM, 5,6-carboxyfluorescein. N.D., not determined.
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YSPTSPS; Fig 2A–C; Table 1). We used this peptide with a single
phosphorylation to avoid binding in multiple registers that would
complicate NMR data analyses. The resulted structure of Rtt103p
CID is formed by eight a-helices in a right-handed superhelical
arrangement (Fig 2A and B), out of which helices a2, a4 and a7
contact the pThr4-CTD peptide at residues P6a, S7a, Y1b, P3b, pT4b,
S7b and Y1c (Figs 2B and C, and EV1). This minimal CTD-binding
moiety binds Rtt103p CID with a KD of 18  1 lM (assayed by FA),
which is almost identical as pThr4-CTD used for structural
determination. The structure is similar to the one of Rtt103p CID–
pSer2-CTD complex [20] in terms of the overall CID fold and the
conformation of the N-terminal part of the CTD peptide, but entirely
different for the C-terminal part of the CTD peptide (Figs 3, EV1,
and EV2).
Recognition of the phospho-threonine CTD by Rtt103p
The upstream part of the pThr4-CTD peptide adopts a b-turn confor-
mation at S2bP3bpT4bS5b and docks into a hydrophobic pocket of the
Rtt103p CID that is formed by Ile22, Tyr62, His66, Val109 and
Ile112, using Y1b and P3b residues (Fig 2B and C). The peptide
conformation in the hydrophobic pocket is further stabilized by a
hydrogen bond between hydroxyl of Y1b and the side-chain amide
of Asn65. This hydrophobic pocket of Rtt103p is highly conserved,
and mutations of residues Tyr62 and His66 (not affecting the struc-
tural integrity; Fig EV3) completely abolish the binding with pThr4-
CTD (Figs 2D and EV4). P3b is inserted into the hydrophobic pocket
next to Val109 and has a trans conformation of the S2bP3b peptidyl-
prolyl bond. As a result of this arrangement, both the S2b and pT4b
side chains are positioned closely to each other in the solvent
exposed area and form intramolecular hydrogen bond between the
hydroxyl group of S2b and phospho-group of T4b. The phospho-
group of pT4b forms a hydrogen bond with the guanidinium group
of Arg108. This is a critical interaction with the pThr4 mark, as con-
firmed by the affinity data for the Arg108Asn mutant (Fig 2D). Akin
to Rtt103p, also other CID-containing proteins such as SCAF4/8
[22], RPRD1A/1B/2 [21] and CHERP [21] contain the equivalent
arginine in the CID pocket. It will be interesting to see whether these
human proteins really recognize pThr4-CTD as well and whether
the pThr4 mark is relevant to their functions. Other CID-containing
proteins in yeast, such as Nrd1p and Pcf11p, do not contain the
equivalent arginine and these proteins were absent in the pThr4-
CTD interactome [18].
Remarkably, we observed multiple strong intermolecular NOEs
among the aromatics of Y1c in the downstream region of the CTD
peptide and the C-terminal parts of helices a4 and a7 (Figs 2C, EV1,
and EV5). The interaction of Y1c at the tip of helices a4 and a7
creates a second turn in the peptide at residues pT4bS5bP6bS7b, bring-
ing two backbone carbonyl groups in close proximity and allows for
their interaction with the guanidinium group of Arg116 (Figs 2B and
C, and EV1). The side chain of Y1c forms numerous hydrophobic
contacts with Lys72, Gly73, Ile118. Arg116Glu and Lys72Glu charge
swapping mutants cause affinity drop of KD = 107  23 lM and
KD = 54  3 lM, respectively (Fig 2D). The similar arrangement of
the downstream region of the CTD was observed in the crystal struc-
ture of close human homologue of Rtt103p CID, RPRD1A, where the
arginine forms a hydrogen bond with carbonyl of T4b and P6b [21].
The Arg116 position is conserved in RPRD1A/1B (Arg114) and
RPRD2 (Arg130) (Fig EV4) [21]. Interestingly, the coordination of
tyrosine from the third heptad repeat Y1c was not observed previ-
ously in the structure of Rtt103p CID bound to the CTD with Ser2
phosphorylation [20]. The previous study used a CTD peptide














Intermolecular distance restraints 47
Total dihedral angle restraintsa 198
Structure statisticsb
Violations (mean and s.d.)
Number of distance restraint violations > 0.5 Å 0.10  0.31
Number of dihedral angle restraint violations > 15° 13.8  2.33
Maximum dihedral angle restraint violation (°) 39.57  9.55
Maximum distance constraint violation (Å) 0.30  0.12
Deviations from idealized geometryb
Bond lengths (Å) 0.00355  0.00008
Bond angles (°) 1.702  0.012
Average pairwise r.m.s.d. (Å)b
Rtt103p CID (7–12; 19–31; 36–48; 54–73; 77–94;
100–116; 121–133)
Heavy atoms 0.91  0.13
Backbone atoms 0.25  0.05
CTD (143–152)
Heavy atoms 2.06  0.42
Backbone atoms 1.42  0.34
Complex
All complex heavy atoms 1.12  0.16
All complex backbone atoms 0.61  0.14
Ramachandran plot statisticsc
Residues in most favoured regions (%) 88.5
Residues in additionally allowed regions (%) 10.1
Residues in generously allowed regions (%) 0.9
Residues in disallowed regions (%) 0.5
aa-helical dihedral angle restraints imposed for the backbone based on the
CSI.
bCalculated for an ensemble of the 20 lowest energy structures.
cBased on PROCHECK analysis [42].
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lacking the complete binding moiety (PS YSPTSPS Y) that possibly
precluded the accommodation of the downstream part of CTD
peptide including the second tyrosine (Y1c; Fig EV1). The compar-
ison of chemical shift perturbations of Rtt103p upon binding to the
singly phosphorylated pSer2-CTD and pThr4-CTD peptides with
complete binding moiety suggests similar accommodation of down-
stream region of both peptides (Fig EV2).
Cis-trans equilibrium of the Ser–Pro prolyl-peptidyl bond
We also tested as to whether two proximal phosphorylation marks
(pSer2/pThr4) on the CTD peptide can alter the cis-trans equilib-
rium of the neighbouring prolyl-peptidyl bond (Fig EV6A). It has
been shown that the cis-trans equilibrium of the CTD is critical for
its recognition by cognate proteins [23–25] and the trans confor-
mation of the Ser–Pro prolyl-peptidyl bond is required for the b-
turn formation [20,23,26,27]. To exclude the possibility that a
highly populated cis conformer would attenuate the binding of the
CTD peptide with two phospho-marks, we assayed the conforma-
tional population of mono- and diphosphorylated peptides using
the [1H,13C]-HSQC spectra of PS Y(pS)13CP(pT)SPS YS and PS
YS13CP(pT)SPS YS peptides, where all P3b carbons were
13C-isoto-
pically labelled (Fig EV6B). In case of pThr4-CTD, we observed
6.6% of the cis conformer. We obtained virtually identical number
for the pSer2pThr4-CTD peptide, where the cis conformation was
populated at 7.8%. Our data suggest that the double phosphoryla-
tion at pSer2/pThr4 of the CTD does not influence the ratio of cis-
trans conformers. Next, we titrated the PS YS13CP(pT)SPS YS
peptide with Rtt103p CID and monitored the titration by [1H,13C]-
HSQC experiment (Fig EV6C). The spectra show the disappearance
of peaks that correspond to the cis conformation during titration,
indicating a shift in the cis-trans equilibrium towards the trans
conformation of the S2b–P3b prolyl-peptidyl bond that is required
for the b-turn formation. The peaks corresponding to the trans
conformation of P3b moved upon titration with protein, reflecting
the accommodation of the proline in the hydrophobic pocket of
Rtt103p CID.
CTD code degeneration
The complex of Rtt103p CID–pThr4-CTD reported here represents
the first structure capturing the recognition of the CTD phosphory-
lated at threonine and explains the structural basis of why Rtt103p
can be a part of the pSer2- and pThr4-CTD interactomes. Previous
reports suggested that Thr4 phosphorylations could interfere with
CTD binding by destabilizing the b-turn conformation that is
required for CTD binding [17,26]. However, our structure shows
that the pThr4 mark is directly recognized by Rtt103p and also that
the phosphate group of pThr4 forms intramolecular hydrogen bond
stabilizing the bound CTD conformation. This conformation
involves the b-turn at S2bP3bpT4bS5b that is a prerequisite for an
effective docking into the hydrophobic pocket of Rtt103p CID
(Figs 2B and C, and 3). Interestingly, the intramolecular hydrogen
bond that stabilizes the b-turn mirrors the one of the Ser2 phospho-
rylated CTD bound to Rtt103p (Fig 3B). The Rtt103p Arg108Asn
mutant has also a similar drop in affinity for pThr4-CTD and pSer2-
CTD, KD = 38  2 lM and KD = 44  2 lM, respectively. These
observations suggest that CTD modifications preventing intramolec-
ular stabilization of the b-turn should negatively affect CTD binding.
Indeed, we observed that doubly phosphorylated CTD at Ser2 and
Thr4 binds to Rtt103p as weak as unmodified CTD (Fig 1). Electro-
static repulsion between closely arranged phosphates of pSer2 and
pThr4 interfere with the formation of the bound CTD conformation
and the peptide with pSer2/pThr4 marks cannot be accommodated
in the binding pocket of Rtt103p (Fig 3). In support of this, the coex-
istence of the pSer2/pThr4 marks in the same repeat has not been
detected by recent mass-spectrometry analysis of RNAPII CTD popu-
lation pulled down by Rtt103p [11]. Our structure also explains
lethality of the Thr4Glu CTD mutant in yeast [18]. Permanent
substitution for glutamate mimics Thr4 phosphorylation that inter-
feres with Ser2 phosphorylation, which consequently prevents bind-
ing of the CTD to cognate proteins as described above.
The individual letters of the CTD code have so far been
associated with unique information translated to stimulation or















pT4 recognition pS2 recognition
Figure 3. Degeneracy of the CTD code.
A Superposition of pThr4-CTD (magenta; PDB ID: 5LVF) and pSer2-CTD (yellow; PDB ID: 2L0I) peptides on the Rtt103p CID surface (grey). N- and C-termini of the
peptides are indicated.
B Close view on the phospho-recognition site of Rtt103p CID. Interaction of pThr4- (magenta sticks, left) and pSer2-CTD (yellow sticks, right) peptides with Arg108
(grey). Hydrogen bonds of the phospho-groups are indicated with black dashed lines.
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CID–pThr4-CTD structure with the Rtt103p CID–pSer2-CTD complex
shows fascinating feature that the same interaction pocket of
Rtt103p can read two different phosphorylation patterns of the CTD
(pSer2 and pThr4) using the same mechanism and involves the
same residues (mainly Arg108; Fig 3). Based on our structural find-
ings, we suggest that the CTD code can be degenerated when read
by CID-containing proteins. In other words, the recruitment of a
single CTD-binding factor may be coded by more than one letter of
the CTD code. As a consequence of this redundancy, CID-containing
CTD-binding factors can be recruited to the poorly conserved heptad
repeats of the CTD (e.g. the CTD of fruit fly) or they can tolerate
some errors or imperfections in phosphorylation of the CTD
[1,3,28].
Materials and Methods
Cloning and protein purification
pET28b-Rtt103p CID was a gift from B. Lunde [20]. Rtt103p CID
point mutants were obtained by QuikChange site-directed mutagen-
esis kit (Stratagene). Resulting constructs were verified by DNA
sequencing and then transformed into E. coli BL21-Codon Plus
(DE3)-RIPL cells (Stratagene). Rtt103p CID (3-131–6xHIS) was
expressed and purified as previously described [20].
NMR measurements and structure determination
All NMR spectra for the backbone and side-chain assignments were
recorded on Bruker AVANCE III HD 950, 850 and 700 MHz spec-
trometers equipped with cryoprobes at a sample temperature of
20°C using 1 mM uniformly 15N,13C-labelled Rtt103p CID in 35 mM
KH2PO4, 100 mM KCl, pH 6.8 (20°C) (90% H2O/10% D2O). Initial
backbone resonance frequency assignment was transferred from
BMRB entries 17044 and 16411 and confirmed by HNCA spectrum.
The spectra were processed using TOPSPIN 3.2 (Bruker Biospin),
and the protein resonances were assigned manually using Sparky
software (Goddard T.G. and Kneller D.G., University of California,
San Francisco). For the assignment of the side-chain proton and
carbon resonances, 4D version of HCCH TOCSY [29] was measured
with a non-uniform sampling. Acquired data were processed and
analysed analogously as described previously [30,31].
All distance constraints were derived from the three-dimensional
15N- and 13C-edited NOESYs collected on a 950 MHz spectrometer.
Additionally, intermolecular distance constraints were obtained
from the three-dimensional F1-
13C/15N-filtered NOESY-[13C,1H]-
HSQC experiment [32,33], with a mixing time of 150 ms on a
950 MHz spectrometer. The NOEs were semi-quantitatively classi-
fied based on their intensities in the 3D NOESY spectra. The initial
structure determinations of the Rtt103p-CTD complex were
performed with the automated NOE assignment module imple-
mented in the CYANA 3.97 program [34]. Then, the CYANA-gener-
ated restraints along with manually assigned protein-CTD
intermolecular restraints were used for further refinement of the
preliminary structures with AMBER16 software [35]. These calcula-
tions employed a modified version (AMBER ff14SB) of the force
field [36], using a protocol described previously [37,38]. The 20
lowest energy conformers were selected (out of 50 calculated) to
form the final ensemble of structures. The atomic coordinates for
the NMR ensemble of the Rtt103p CID-pThr4-CTD complex have
been deposited in the Protein Data Bank under ID code 5LVF and in
Biological Magnetic Resonance Bank under ID code 34041. Molecu-
lar graphics were generated using PyMOL (The PyMOL Molecular
Graphics System, Version 1.8 Schrödinger, LLC).
Fluorescence anisotropy
The equilibrium binding of Rtt103p CID constructs to differently
phosphorylated CTD was analysed by fluorescence anisotropy. The
CTD peptides were N-terminally labelled with the 5,6-carboxyfluor-
escein (FAM). The measurements were conducted on a FluoroLog-3
spectrofluorometer (Horiba Jobin-Yvon Edison, NJ). The instrument
was equipped with a thermostatted cell holder with a Neslab RTE7
water bath (Thermo Scientific). Samples were excited with vertically
polarized light at 467 nm, and both vertical and horizontal emis-
sions were recorded at 516 nm. All measurements were conducted
at 10°C in 35 mM KH2PO4, 100 mM KCl (pH 6.8). Each data point is
an average of three measurements. The experimental binding
isotherms were analysed by DynaFit using 1:1 model with non-
specific binding [39].
Cis-trans population estimation
For the estimation of the cis-trans population of conformers around
the Ser-Pro peptide bond, aliphatic [13C,1H]-HSQC was collected
using 1 mM sample of peptide PSYS13CP(pT)SPSYS or PSY(pS)13CP
(pT)SPSYS in 35 mM KH2PO4, 100 mM KCl (pH 6.8) in 90% H2O/
10% D2O at 20°C on Bruker AVANCE III HD 700 MHz spectrometer.
For the [13C,1H]-HSQC titration experiment, 0.2 mM PSYS13CP(pT)
SPSYS peptide was used and 1.2 mM Rtt103p CID stock was added.
1H-13Cc and
1H-13Cb peaks were integrated using Sparky routine
(Goddard T.G. and Kneller D.G., University of California, San Fran-
cisco). Population was estimated as a ratio of the peak volume of a
given conformation to the sum of volumes of all conformations.
Determination of chemical shift perturbation (CSP) value
Chemical shift perturbation (CSP) value is defined as the normalized
length of a vector Ej, whose components are differences dji between
observed chemical shifts (bound form) and chemical shifts from a
reference experiment (free form). Index j represents the amino acid
type within the primary sequence of the protein. Weight factors for
each atom type wH = 1 and wN = 0.15 were used.
Ej






Peptides used in the study
The following peptides were synthesized by JPT (Berlin, DE)
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Expanded View for this article is available online.
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